3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Sarcoma
5
Lymphoma, Follicular
5
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Tertiary Lymphoid Structures
1
Solid Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tertiary Lymphoid Structures
×
tazemetostat
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled